Hemab Therapeutics Holdings, Inc. Common Stock (COAG) - Net Assets
Based on the latest financial reports, Hemab Therapeutics Holdings, Inc. Common Stock (COAG) has net assets worth $- USD as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($-) and total liabilities ($-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hemab Therapeutics Holdings, Inc. Common (COAG) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Hemab Therapeutics Holdings, Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how Hemab Therapeutics Holdings, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore COAG total assets for the complete picture of this company's asset base.
Annual Net Assets for Hemab Therapeutics Holdings, Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Hemab Therapeutics Holdings, Inc. Common Stock from 2024 to 2025. For live valuation and market cap data, see market value of Hemab Therapeutics Holdings, Inc. Common.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-176.63 Million | -53.23% |
| 2024-12-31 | $-115.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hemab Therapeutics Holdings, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6391300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $5.22 Million | % |
| Total Equity | $-176.63 Million | 100.00% |
Hemab Therapeutics Holdings, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Hemab Therapeutics Holdings, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vulcan Energy Resources Ltd
AU:VUL
|
$1.17 Billion |
|
Avia Avian PT Tbk
JK:AVIA
|
$1.17 Billion |
|
Teekay Corporation
NYSE:TK
|
$1.17 Billion |
|
Malion New Materials Co Ltd
SHE:300586
|
$1.17 Billion |
|
Hanza AB
ST:HANZA
|
$1.17 Billion |
|
ArcherMind Technology Nanjing Co Ltd
SHE:300598
|
$1.17 Billion |
|
Mineros SA
TO:MSA
|
$1.17 Billion |
|
Juewei Food Co Ltd
SHG:603517
|
$1.17 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hemab Therapeutics Holdings, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -115,273,000 to -176,635,000, a change of -61,362,000.
- Net loss of 63,913,000 reduced equity.
- New share issuances of 156,421,000 increased equity.
- Other factors decreased equity by 153,870,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-63.91 Million | -36.18% |
| Share Issuances | $156.42 Million | +88.56% |
| Other Changes | $-153.87 Million | -87.11% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Hemab Therapeutics Holdings, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $-2.72 | $26.30 | x |
| 2025-12-31 | $-4.16 | $26.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hemab Therapeutics Holdings, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-37.18 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-46.25 Million |
Industry Comparison
This section compares Hemab Therapeutics Holdings, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,374,297
- Average return on equity (ROE) among peers: -386.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $- | 0.00% | N/A | $1.17 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $98.20 Million |
| Abcellera Biologics Inc (ABCL) | $1.14 Billion | -12.83% | 0.19x | $1.57 Billion |
| Abeona Therapeutics Inc (ABEO) | $681.00K | -3192.95% | 12.43x | $313.99 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $179.85 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $793.56 Million |
| Arbutus Biopharma Corp (ABUS) | $26.88 Million | -30.41% | 0.07x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $84.98 Million | -24.53% | 0.28x | $3.65 Billion |
About Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombast… Read more